Connect

Partner News

Partner News

DHHS Funding Opportunities

FUNDING OPPORTUNITIES from the Department of Health and Human Services (DHHS)

________________________________________________________

Department of Health and Human Services – Administration for Community Living – ACL National Falls Prevention Resource Center

Proposal Due Date: April 29, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $1,000,000

Award Ceiling: $1,000,000

Award Floor: $1,000,000

Funding Opportunity Number: HHS-2021-ACL-AOA-FPSG-0019

Purpose: Through this funding opportunity, the Administration on Aging (AoA), part of the Administration for Community Living (ACL), plans to award one cooperative agreement, with two goals: Goal 1: Provide technical assistance, education, and resources to increase public awareness about the risk of falls and how to prevent them, as well as increase the number of older adults and adults with disabilities who participate in evidence-based falls prevention programs. Goal 2: Support the development and enhancement of integrated, sustainable service networks within states, regions, and tribes that provide evidence-based falls prevention programs, as well as related services that address the social and behavioral determinants of health of older adults and adults with disabilities.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=329746

Department of Health and Human Services – Administration for Community Living – Disability and Rehabilitation Research Projects (DRRP) Program: National Research Center for Parents with Disabilities

Proposal Due Date: May 7, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $500,000

Award Ceiling: $500,000

Award Floor: $495,000

Funding Opportunity Number: HHS-2021-ACL-NIDILRR-DPCP-0060

Purpose: The purpose of NIDILRR’s Disability and Rehabilitation Research Projects (DRRP) which are funded through the Disability and Rehabilitation Research Projects and Centers Program, is to plan and conduct research, demonstration projects, training, and related activities, including international activities, to develop methods, procedures, and rehabilitation technology that maximize the full inclusion and integration into society, employment, independent living, family support, and economic and social self-sufficiency of individuals with disabilities, especially individuals with the most severe disabilities, and to improve the effectiveness of services authorized under the Rehabilitation Act of 1973, as amended (Rehabilitation Act).

Under this particular DRRP priority, the Center must conduct research and related activities toward services, technologies, and other interventions to support parents with disabilities in their parenting roles.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=330451

Department of Health and Human Services – Centers for Disease Control – Preventing Violence Affecting Young Lives (PREVAYL)

Proposal Due Date: May 1, 2021

Expected Number of Awards: 8

Estimated Total Program Funding: $10,000,000

Award Ceiling: $250,000

Award Floor: $225,000

Funding Opportunity Number: CDC-RFA-CE21-2104

Purpose: The purpose of this funding is to address multiple forms of violence impacting adolescents and young adults, particularly in communities with high rates of violence, by implementing prevention approaches with an emphasis on the outer levels of the social-ecological model (i.e., community/societal levels). PREVAYL requires recipients to implement community/societal level strategies and approaches that address multiple forms of violence impacting adolescents and young adults, develop and/or enhance a jurisdictional violence prevention strategic plan, develop and implement an evaluation plan, develop a sustainability plan, and participate in a multi-sector coalition. In addition, this funding will address risk factors such as social determinants of health (e.g., concentrated poverty, limited educational/employment opportunities) and racial inequity (e.g., structural, systemic, and institutional racism).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=329981

Department of Health and Human Services – Centers for Disease Control – NCIRD Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities outside the United States

Proposal Due Date: May 4, 2021

Expected Number of Awards: 60

Estimated Total Program Funding: $120,000,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: CDC-RFA-IP21-2101

Purpose: This notice of funding opportunity (NOFO) continues work initiated under influenza cooperative agreements IP16-1603, IP16-1605, IP19-1902 and previous awards from years 2004 – 2015. These agreements were developed to enhance the ability and capacity of foreign governments to conduct surveillance for seasonal influenza and to detect and respond to pandemic influenza threats. The proposed NOFO complements current global pandemic preparedness work and seeks to further strengthen the capacity of national health authorities and partners to detect and respond to influenza outbreaks and on a broader scale to respond to respiratory pathogen outbreaks utilizing as needed the influenza surveillance systems as a surveillance base. 

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331960

Department of Health and Human Services – Food and Drug Administration – Data Standards for Tobacco Research and Scientific Review Program (U24) Clinical Trial Not Allowed

Proposal Due Date: June 2, 2021

Expected Number of Awards: 3

Estimated Total Program Funding: $750,000

Award Ceiling: $750,000

Award Floor:

Funding Opportunity Number: RFA-FD-22-002

Purpose: The FDA Center for Tobacco Products is encouraging applications for projects to expedite development of data standards and terminologies to facilitate tobacco research, scientific review, harm reduction, and information exchange. The primary objective is to facilitate the development of non-proprietary, consensus-based, standards for use in studies of tobacco products. Projects may focus on solutions to general data standards development and implementation challenges and/or on specific concepts, domains or areas where standardization is needed.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331906

Department of Health and Human Services – Health Resources and Services Administration – Behavioral Health Workforce Development Technical Assistance and Evaluation (BHWD TAE) Program

Proposal Due Date: May 3, 2021

Expected Number of Awards: 1

Estimated Total Program Funding: $2,500,000

Award Ceiling: $0

Award Floor: $0

Funding Opportunity: Number: HRSA-21-086

Purpose: This notice announces the opportunity to apply for funding under the Behavioral Health Workforce Development Technical Assistance and Evaluation (BHWD TAE) Program.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=329871

Department of Health and Human Services – Health Resources and Services Administration – Long-term Follow-up for Severe Combined Immunodeficiency and Other Newborn Screening Conditions

Proposal Due Date: May 3, 2021

Expected Number of Awards: 6

Estimated Total Program Funding: $3,000,000

Award Ceiling: $500,000

Award Floor:

Funding Opportunity Number: HRSA-21-079

Purpose: This notice announces the opportunity to apply for funding under the Long-term Follow-up for Severe Combined Immunodeficiency and Other Newborn Screening Conditions program. The goal of this program is to ensure that newborns and children identified through newborn screening (NBS) achieve the best possible outcomes by expanding the ability of state public health agencies to provide screening, counseling and services to these newborns and children and to collaborate with clinicians, public health agencies and families to create a system of care that can assess and coordinate follow-up and treatment of newborn screening conditions.1 This NOFO supports this goal by making available funding to support comprehensive models of long-term follow-up (LTFU) that demonstrate collaborations between clinicians, public health agencies, and families.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331850

Department of Health and Human Services – Health Resources and Services Administration – State Newborn Screening Interoperability Implementation Program

Proposal Due Date: May 10, 2021

Expected Number of Awards: 4

Estimated Total Program Funding: $800,000

Award Ceiling:

Award Floor:

Funding Opportunity Number: HRSA-21-085

Purpose: The Health Resources and Services Administration (HRSA) is accepting applications for the fiscal year (FY) 2021 for the State Newborn Screening Interoperability Implementation Program. The purpose of this program is to support state newborn screening programs in the implementation of comprehensive data interoperability plans to ensure infants having or at risk for heritable disorders are provided with the appropriate screening, counseling, and/or health care services. Interoperability is defined as the ability of different information systems, devices and applications (‘systems’) to access, exchange, integrate, and cooperatively use data in a coordinated manner, within and across organizational, regional, and national boundaries, to provide timely and seamless portability of information and optimize the health of individuals and populations globally.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331851

Department of Health and Human Services – National Institutes of Health – Limited Competition: NEI – DOD Vision Research Collaborative (R01 Clinical Trial Optional)

Proposal Due Date: April 22, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-161

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to establish a joint initiative between the National Eye Institute (NEI) and the Vision Research Program (Vision Research Program) of the Department of Defense (DOD). Through this FOA, the NEI will support meritorious VRP proposals that were unable to be funded by the DOD.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331914

Department of Health and Human Services – National Institutes of Health – Firearm Inquiry and Morality Prevention Research (R01 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: April 30, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-192

Purpose:  Nearly 40,000 people in the U.S. die from firearm-related deaths each year, primarily from suicide (60%) or homicide (37%), and many more have experienced non-fatal firearm injuries, both intentional and nonintentional. The Joint Explanatory Statement accompanying the Consolidated Appropriations Act, 2021 (Public Law 116-260) included funding for the NIH to conduct research on firearm injury and mortality prevention and recommended that NIH take a comprehensive approach to studying the underlying causes and evidence-based methods of prevention of firearm injury, including crime prevention. Within the legislative mandates and limitations of NIH funding (NOT-OD-21-058, NOT-OD-21-056), the NIH encourages research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including both victims and perpetrators), the development and evaluation of innovative interventions to prevent firearm injury and mortality, and the examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331938

Department of Health and Human Services – National Institutes of Health – Firearm Injury and Morality Prevention Research (R21/R23 Clinical Trial Optional)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: April 30, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-191

Purpose: Nearly 40,000 people in the U.S. die from firearm-related deaths each year, primarily from suicide (60%) or homicide (37%), and many more have experienced non-fatal firearm injuries, both intentional and nonintentional. The Joint Explanatory Statement accompanying the Consolidated Appropriations Act, 2021 (Public Law 116-260) included funding for the NIH to conduct research on firearm injury and mortality prevention and recommended that NIH take a comprehensive approach to studying the underlying causes and evidence-based methods of prevention of firearm injury, including crime prevention. Within the legislative mandates and limitations of NIH funding (NOT-OD-21-058, NOT-OD-21-056), the NIH encourages research to improve understanding of the determinants of firearm injury, the identification of those at risk of firearm injury (including both victims and perpetrators), the development and piloting of innovative interventions to prevent firearm injury and mortality, and the examination of approaches to improve the implementation of existing, evidence-based interventions to prevent firearm injury and mortality.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331958

Department of Health and Human Services – National Institutes of Health – NIOSH Support for Conferences and Scientific Meetings (U13 Clinical Trial Not Allowed)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: April 30, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-193

Purpose: The purpose of the NIOSH Support for Conferences and Scientific Meetings (U13) is to support high quality scientific meetings, conferences, and workshops that are relevant to NIOSHs scientific mission and that promote occupational safety and health, NIOSH program priorities, and public health. The conference program is integral to the overall mission of NIOSH. An application should address and advance important areas of research in the field of occupational safety and health of particular interest to NIOSH programs and the National Occupational Research Agenda.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331936

Department of Health and Human Services – National Institutes of Health – AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed)

Proposal Due Date: May 25, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $400,000

Award Floor:

Funding Opportunity Number: PAR-21-141

Purpose: It is essential to expand and diversify the skilled AD/ADRD clinical trial workforce. The intent of this Funding Opportunity Announcement (FOA) is to encourage applications that develop creative and innovative short courses to train the next generation of AD/ADRD clinical trialists in state-of-the-art clinical research skills.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331897

Department of Health and Human Services – National Institutes of Health – Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: June 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-132

Purpose: This is a reissue of RFA-MH-18-707: Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required). As part of NIMH’s clinical trials pipeline FOAs, this announcement supports confirmatory efficacy testing of non pharmacological therapeutic and preventive interventions for mental disorders in adults and children that address unmet therapeutic needs, and are consistent with the NIMH emphasis on the experimental therapeutics approach. In this approach, clinical trials should be designed to increase knowledge of the relationship between underlying disease processes and the mechanisms of action through which any intervention produces therapeutic change.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331834

Department of Health and Human Services – National Institutes of Health – Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: June 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-134

Purpose: This is a reissue of RFA-MH-18-705: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required). As part of NIMH’s clinical trials pipeline, this FOA encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH’s emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331832

Department of Health and Human Services – National Institutes of Health – Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: June 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-136

Purpose: This is a reissue of RFA-MH-18-703: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required). NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this FOA encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331840

Department of Health and Human Services – National Institutes of Health – Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: June 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-137

Purpose: This is a reissue of RFA-MH-18-702: Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required). NIMH requires an experimental therapeutics approach for the development and testing of therapeutic interventions, in which studies both evaluate the clinical effect of an intervention and generate information about the mechanisms underlying a disorder or an intervention response. As part of NIMHs Clinical Trial Pipeline, this FOA encourages early stage testing of pharmacologic interventions with novel mechanisms of actions or device-based interventions. More specifically, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331858

Department of Health and Human Services – National Institutes of Health – Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: June 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-130

Purpose: This is a reissue of RFA-MH-18-701: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required). This FOA is a key element of NIMHs set of FOAs to support clinical trials research across the intervention development and testing pipeline. The FOA supports (1) clinical trials to test the effectiveness of optimized therapeutic and preventive interventions for use in community and practice settings; and (2) clinical trials to evaluate the effectiveness of patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of mental health services.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331831

Department of Health and Human Services – National Institutes of Health – Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: June 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-129

Purpose: This is a reissue of RFA-MH-18-700: Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01– Clinical Trial Required). This FOA is a key element of NIMHs set of FOAs to support clinical trials research across the intervention development and testing pipeline. The FOA supports (1) clinical trials to test the effectiveness of optimized therapeutic and preventive interventions for use in community and practice settings; and (2) clinical trials to evaluate the effectiveness of patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of mental health services.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331856

Department of Health and Human Services – National Institutes of Health – Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: June 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-135

Purpose: This is a reissue of RFA-MH-18-704: Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required). As part of NIMH’s clinical trials pipeline, this FOA encourages pilot research developing and testing novel psychosocial interventions and/or targets. Consistent with NIMH’s emphasis on the experimental therapeutics approach to intervention development, it intends to speed the translation of emergent research in basic, behavioral, cognitive, affect, and neuropsychological science into preventative or therapeutic interventions. This RFA will provide up to two years of support for evaluation of target engagement and establishment of intervention parameters, and up to three years of support to replicate target engagement from prior studies and to test the association between target engagement and change in clinical outcome(s).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331839

Department of Health and Human Services – National Institutes of Health – Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Requirement)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: June 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-131

Purpose: This is a reissue of RFA-MH-18-706: Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required). As part of NIMH’s clinical trials pipeline FOAs, this announcement encourages pilot effectiveness studies focused on 1) optimizing the effectiveness of preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) developing and preliminary testing innovative services interventions. Consistent with the NIMH experimental therapeutics approach, this FOA is intended to support pilot studies of intervention effectiveness or service delivery approaches that explicitly address whether the intervention engages the target(s)/mechanism(s) presumed to underlie the intervention effects (i.e., the mechanism(s) that accounts for changes in clinical/functional outcomes, changes in provider behavior, improved access or continuity of services, etc.).

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331835

Department of Health and Human Services – National Institutes and Human Services – First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U10 Clincal Trial Required)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: June 15, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-133

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs, or novel neuromodulatory devices for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase II studies of novel agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. Phase II/PoC studies must evaluate the drugs impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to “de-risk” novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private or other public funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331814

Department of Health and Human Services – National Institutes of Health – NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

Letter of Intent Due Date: 30 days prior to the application due date

Proposal Due Date: June 18, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: PAR-21-160

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to seek UG3/UH3 phased cooperative agreement research applications to plan and implement clinical trials within the mission of NIDCR. Awards made under this FOA will initially support a one-year milestone-driven planning phase (UG3), with possible transition to a clinical trial implementation phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UH3 phase of the award will support the conduct of one investigator-initiated clinical trial.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331912

Department of Health and Human Services – National Institutes of Health – Tropical Medicine Research Centers Coordinating Center (U01 Clinical Trial Not Allowed)

Proposal Due Date: June 18, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-AI-21-005

Purpose: This Funding Opportunity Announcement (FOA) solicits applications for a Tropical Medicine Research Centers Coordinating Center (TMRC CC) for the Tropical Medicine Research Centers (TMRC). The TMRC CC will oversee and coordinate efforts across the TMRCs related to data management, data and specimen sharing, scientific collaboration, creation and maintenance of a virtual sample repository, organizing annual meetings, managing an Opportunity Fund to support research by junior and early-stage investigators, and liaising with United States Government (USG) counterparts and other stakeholders.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331937

Department of Health and Human Services – National Institutes of Health – Tropical Medicine Research Centers (U01 Clinical Trial Not Allowed)

Proposal Due Date: June 18, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling:

Award Floor:

Funding Opportunity Number: RFA-AI-21-004

Purpose: This funding opportunity announcement (FOA) solicits research applications focused on the etiology, epidemiology, pathogenesis, clinical manifestations, diagnosis, prevention, treatment and control of select Neglected Tropical Diseases (NTDs) in endemic areas. The Tropical Medicine Research Centers (TMRCs) are intended to advance NIAIDs global research effort by targeting research endeavors to: develop novel diagnostic, prevention and therapeutic strategies adapted for the unique needs of low and middle-income countries (LMICs), as classified by the World Bank; create and sustain in-country research capacity; stimulate scientific collaboration and global partnerships; work with in-country scientists to develop training; provide opportunities for junior and early-stage investigators to conduct research on NTDs; and facilitate sample sharing to support translational research to develop or evaluate new drugs, diagnostics, vaccines, therapeutics, or vector control strategies.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331957

Department of Health and Human Services – National Institute of Health – Triadic Interactions in Clinical Encounters Involving People with Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional)

Letter of Intent Due Date: May 23, 2021

Proposal Due Date: June 23, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $500,000

Award Floor:

Funding Opportunity Number: RFG-AG-22-020

Purpose: The goal of this initiative is to support research that can lead to the development of interventions for optimizing communication among patients, caregivers, and health care practitioners, and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD. To these ends, basic research and translational research is solicited in two high-priority areas: (1) effective communications and relationships among patients, healthcare practitioners, and caregivers; and (2) associations between close relationship processes and health in caregiving relationships.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331812

Department of Health and Human Services – Substance Abuse and Mental Health Services Administration – Strategic Prevention Framework for Prescription Drugs

Proposal Due Date: April 30, 2021

Expected Number of Awards: 26

Estimated Total Program Funding: $10,000,000

Award Ceiling: $384,000

Award Floor:

Funding Opportunity Number: SP-21-001

Purpose: The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Prevention (CSAP), is accepting applications for fiscal year (FY) 2021 Strategic Prevention Framework for Prescription Drugs (Short Title: SPF Rx) grant program. The SPF Rx grant program provides an opportunity for states, U.S. territories, (herein referred to as “states”), and Tribal entities that have completed a Strategic Prevention Framework State Incentive Grant (SPF SIG) to target the priority issue of prescription drug misuse or another state-level strategic planning process around prescription drug misuse prevention. The program is designed to raise awareness about the dangers of sharing medications and work with pharmaceutical and medical communities on the risks of overprescribing to young adults. The SPF Rx program will also raise community awareness and bring prescription drug abuse prevention activities and education to schools, communities, parents, prescribers, and their patients. In addition, SAMHSA will track reductions in opioid overdoses and the incorporation of Prescription Drug Monitoring Program (PDMP) data into needs assessments and strategic plans as indicators of the program’s success.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=330030

Department of Health and Human Services – National Institutes of Health – The RADx-UP CCDC Rapid Research Pilot Program

Proposal Due Date: Rolling, first Letter of Intent due date is March 26, 2021 and first full application due date is April 16, 2021

Expected Number of Awards:

Estimated Total Program Funding:

Award Ceiling: $200,000

Award Floor:

Funding Opportunity Number:

Purpose: Duke University in partnership with the University of North Carolina, Chapel Hill, is serving as the Coordination and Data Collection Center (CDCC) for the National Institutes of Health (NIH)-supported Rapid Acceleration of Diagnostics- Underserved Populations (RADx-UP) program. The goal of the program is to improve access to and uptake of diagnostic COVID-19 testing in communities of underserved and vulnerable populations. The purpose of the overall program is to better understand factors that have led to the disproportionate impact of COVID-19 on these groups, and develop interventions to reduce those disparities. The RADx-UP program has multiple components, which are summarized here.

For the purpose of this RFA, populations that are underserved as well as populations that are COVID-19 vulnerable due to medical, geographic, and social factors, are defined below:

Underserved: NIH-designated health disparity populations known to experience barriers to accessing health coverage and basic health care services as well as disparities from COVID-19. A full description can be found here.

COVID-19 medically and/or socially vulnerable populations: Residents of nursing homes and assisted living facilities; community-dwelling older adults; individuals with intellectual, developmental, sensory, or physical disabilities, cognitive impairment or dementia, or communication disorders; homeless populations; individuals involved with the criminal or juvenile justice systems (incarcerated or under community supervision); individuals with medical comorbidities known to increase risk of severe COVID-19, including heart failure and related cardiovascular conditions, diabetes mellitus, chronic lung disease, moderate or severe obesity, HIV/AIDS; pregnant and post-partum women; children and adolescents; individuals living in congregate housing such as shelters or residential treatment facilities; individuals in overcrowded or public housing; individuals with substance use disorders or serious mental illness; migrant and immigrant communities; residents of tribal lands or reservations; communities exposed to high rates of air pollution or other toxic exposures; and rural and remote communities.

The CDCC is pleased to solicit applications for its Rapid Research Pilot Program. This RFA describes the first solicitation of the CDCC Rapid Research Pilot Program. This pilot program provides an expedited funding mechanism (CDCC subawards) to evaluate the feasibility of implementing emerging COVID-19 testing technologies in underserved communities.

The CDCC Rapid Research Pilot Program seeks an applicant pool that draws from the rich diversity of communities, populations, and groups in the U.S including the U.S. territories, tribal nations or organizations (American Indians, Alaska Natives, Native Hawaiians, and Other Pacific Islanders). To this end, we encourage those that are interested in this funding opportunity to review the FAQ list and provide questions for the Q&A document that will be shared and posted to the program website.

Applicants to the Rapid Research Pilot Program should be familiar with principles of community engagement. Potential applicants unfamiliar with the principles of community engagement can find some initial information here. Community engagement is defined in the Principles of Community Engagement Second Primer as the process of working collaboratively with groups of people who are affiliated by geographic proximity, special interest, or similar situations with respect to issues affecting their well-being, The growing commitment to community engagement is reflected in a number of major federal initiatives, including the Clinical and Translational Science Awards (CTSA) program, and the Research/Centers in Minority Institutions program of the National Institutes of Health (NIH), the CDC’s Prevention Research Centers, and the practice-based research networks of the Agency for Healthcare Research and Quality (AHRQ).

Apply for a Grant